Neuphoria Therapeutics Inc.
NEUP | NASDAQ
$3.05
-$0.01 (-0.33%)
At close: Oct 30, 2026, 4:00 PM ET
$3.05
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2026 Jun 30, 2026 | FY 2025 Jun 30, 2025 | FY 2024 Jun 30, 2024 | FY 2023 Jun 30, 2023 | FY 2022 Jun 30, 2022 | FY 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|
Revenue | 1.17M | 15.65M | n/a | n/a | 383.16K | 927.54K |
Cost of Revenue | 662.96K | 662.89K | 662.99K | 671.48K | 16M | 1.69M |
Gross Profit | 511.21K | 14.99M | -662.99K | -671.48K | -9.98M | -1.27M |
Operating Income | -9.81M | -1.13M | -26.79M | -33.09M | -31.02M | -8.96M |
Interest Income | 665.57K | 166.5K | 220.1K | 486.39K | 9.87K | 4.29K |
Pretax Income | -13.59M | -838K | -15.58M | -32.39M | -31.9M | -6.68M |
Net Income | -13.45M | -369.63K | -15.49M | -32.18M | -22.94M | -6.53M |
Selling & General & Admin | 7.44B | 7.77M | 8.47M | 13.41M | 7.69M | 4.24M |
Research & Development | 3.55B | 9.01M | 14.1M | 19.67M | 23.25M | 4.33M |
Other Expenses | -10.97B | -662.89K | -4.68M | n/a | -7.2M | 2.68M |
Operating Expenses | 10.32M | 16.12M | 17.89M | 33.09M | 23.74M | 11.25M |
Interest Expense | n/a | n/a | n/a | n/a | 26.87K | 1.08M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 262.44K | n/a |
Cost & Expenses | 10.98M | 16.78M | 17.89M | 33.09M | 39.8M | 12.94M |
Income Tax Expense | -139.17K | -468.37K | -87.32K | -209.47K | -278.77K | -140.82K |
Shares Outstanding (Basic) | 4.4M | 1.62M | 149.8M | 122.39M | 112.78M | 65M |
Shares Outstanding (Diluted) | 4.4M | 1.62M | 149.8M | 122.39M | 112.78M | 65M |
EPS (Basic) | -3.06 | -0.23 | -0.10 | -0.24 | -0.20 | -0.10 |
EPS (Diluted) | -3.06 | -0.23 | -0.10 | -0.24 | -0.20 | -0.10 |
EBITDA | -9.15M | -121.9K | -25.65M | -31.45M | -30.25M | -4.51M |
EBIT | -9.81M | -1.13M | -26.64M | -32.45M | -31.86M | -5.79M |
Depreciation & Amortization | 662.96K | 1.01M | 992.56K | 998.17K | 1.61M | 1.28M |
Add to Watchlist
Select watchlists to add or remove NEUP